Zimmer Biomet Downgraded by BTIG on Limited Near-Term Upside

Font: Financial Modeling Prep  • Mar 23, 2026

BTIG downgraded Zimmer Biomet (NYSE: ZBH) to Neutral from Buy and withdrew its $112 price target, citing limited upside potential in the near term.

The firm noted that fiscal 2025 was a challenging year for the company, with shares declining 14.8% despite efforts to improve both growth and profitability.

BTIG said that recently launched products, including the so-called “Magnificent 7,” did not significantly accelerate organic growth during 2025, while Paragon 28 also underperformed expectations.

The downgrade was based primarily on forward-looking concerns, with the firm stating that it does not expect the stock to generate meaningful returns in the coming quarters despite ongoing operational initiatives.

Following recent industry discussions at the AAOS conference, Zimmer Biomet highlighted continued investment in autonomous robotics and showcased its product pipeline. However, BTIG indicated that these developments are unlikely to influence the stock in the near term, as commercialization is not expected until late 2027 or early 2028.

The firm also pointed to a limited product cycle in fiscal 2026 and ongoing salesforce changes as factors that could constrain performance.

While much of this outlook appears reflected in the current valuation, estimated at around 10.5x earnings, BTIG said it is difficult to envision a scenario where the company materially outperforms expectations in fiscal 2026.